Chongqing Zhifei Bio Products (300122) — Financial Flexibility Index
Chongqing Zhifei Bio Products (300122) has a Financial Flexibility Index of 0.10x as of September 2025. Free cash flow of CN¥1.62 Billion (operating CF CN¥1.42 Billion minus capex CN¥202.94 Million) represents 0% of total liabilities (CN¥16.79 Billion). Check Chongqing Zhifei Bio Products investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Chongqing Zhifei Bio Products Financial Flexibility Index (2007–2025)
Historical Financial Flexibility Index trend for Chongqing Zhifei Bio Products across 19 annual periods. For the full cash flow conversion analysis, see Chongqing Zhifei Bio Products (300122) cash flow conversion.
Annual Financial Flexibility Index for Chongqing Zhifei Bio Products (2007–2025)
Year-by-year free cash flow to debt coverage for Chongqing Zhifei Bio Products. Explore Chongqing Zhifei Bio Products (300122) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.37x | CN¥5.79 Billion | CN¥5.17 Billion | CN¥15.61 Billion | ▲ +303.0% |
| 2024 | -0.18x | CN¥-3.48 Billion | CN¥-4.41 Billion | CN¥19.08 Billion | ▼ -133.8% |
| 2023 | 0.54x | CN¥10.13 Billion | CN¥9.00 Billion | CN¥18.73 Billion | ▲ +116.4% |
| 2022 | 0.25x | CN¥3.44 Billion | CN¥1.99 Billion | CN¥13.77 Billion | ▼ -70.3% |
| 2021 | 0.84x | CN¥10.44 Billion | CN¥8.51 Billion | CN¥12.39 Billion | ▲ +35.9% |
| 2020 | 0.62x | CN¥4.32 Billion | CN¥3.50 Billion | CN¥6.97 Billion | ▲ +66.1% |
| 2019 | 0.37x | CN¥1.94 Billion | CN¥1.37 Billion | CN¥5.20 Billion | ▼ -7.8% |
| 2018 | 0.41x | CN¥1.07 Billion | CN¥585.59 Million | CN¥2.63 Billion | ▲ +9.0% |
| 2017 | 0.37x | CN¥434.46 Million | CN¥203.61 Million | CN¥1.17 Billion | ▼ -82.4% |
| 2016 | 2.11x | CN¥398.00 Million | CN¥89.95 Million | CN¥188.21 Million | ▼ 0.0% |
| 2015 | 2.11x | CN¥449.16 Million | CN¥223.45 Million | CN¥212.40 Million | ▲ +23.8% |
| 2014 | 1.71x | CN¥438.34 Million | CN¥161.39 Million | CN¥256.72 Million | ▼ -19.8% |
| 2013 | 2.13x | CN¥422.94 Million | CN¥221.58 Million | CN¥198.61 Million | ▼ -10.9% |
| 2012 | 2.39x | CN¥311.95 Million | CN¥112.89 Million | CN¥130.53 Million | ▼ -34.2% |
| 2011 | 3.63x | CN¥530.81 Million | CN¥221.25 Million | CN¥146.22 Million | ▲ +132.1% |
| 2010 | 1.56x | CN¥105.70 Million | CN¥54.19 Million | CN¥67.59 Million | ▼ -53.4% |
| 2009 | 3.35x | CN¥222.48 Million | CN¥210.61 Million | CN¥66.33 Million | ▲ +132.5% |
| 2008 | 1.44x | CN¥177.47 Million | CN¥141.58 Million | CN¥123.05 Million | ▲ +52.5% |
| 2007 | 0.95x | CN¥136.42 Million | CN¥111.66 Million | CN¥144.27 Million | — |